Literature DB >> 9197393

Toxoplasma gondii virulence markers identified by random amplified polymorphic DNA polymerase chain reaction.

Z G Guo1, U Gross, A M Johnson.   

Abstract

Genomic DNAs from 35 Toxoplasma gondii strains were amplified by random amplified polymorphic DNA (RAPD) polymerase chain reaction (PCR) using 18 arbitrary 10-mer primers. At least four primers were found to generate DNA fragments that discriminate the 35 T. gondii strains into a genotype of virulent strains and a genotype of avirulent strains. Primer B12 was found to generate a virulence-specific fragment and primers B5, C8, and C20 were found to generate avirulence-specific fragments, which in all cases clearly identified either the virulence phenotype or the avirulence phenotype, respectively. In addition, the DNA polymorphic bands detected were analyzed by parsimony and distance analysis. A similar genetic relationship among the T. gondii strains was determined by the two phylogenetic methods, which use completely different assumptions. Consistent with the division of the 35 strains into a genotype of virulent strains and a genotype of avirulent strains, both analyses revealed 2 clonal lineages directly correlated with murine virulence. These results strongly support the hypothesis that the genus Toxoplasma may actually contain two clonal lineages correlated with virulence, which have evolved independently following their initial separation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9197393     DOI: 10.1007/s004360050280

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  9 in total

1.  PCR fingerprinting of Blastocystis isolated from symptomatic and asymptomatic human hosts.

Authors:  T C Tan; K G Suresh; K L Thong; H V Smith
Journal:  Parasitol Res       Date:  2006-04-21       Impact factor: 2.289

2.  Do Toxoplasma gondii RH strain tachyzoites evolve during continuous passage?

Authors:  S Mavin; A W L Joss; J Ball; D O Ho-Yen
Journal:  J Clin Pathol       Date:  2004-06       Impact factor: 3.411

3.  Phosphorylation of mouse immunity-related GTPase (IRG) resistance proteins is an evasion strategy for virulent Toxoplasma gondii.

Authors:  Tobias Steinfeldt; Stephanie Könen-Waisman; Lan Tong; Nikolaus Pawlowski; Tobias Lamkemeyer; L David Sibley; Julia P Hunn; Jonathan C Howard
Journal:  PLoS Biol       Date:  2010-12-21       Impact factor: 8.029

Review 4.  Diagnosis of toxoplasmosis and typing of Toxoplasma gondii.

Authors:  Quan Liu; Ze-Dong Wang; Si-Yang Huang; Xing-Quan Zhu
Journal:  Parasit Vectors       Date:  2015-05-28       Impact factor: 3.876

5.  In vitro maturation of Toxoplasma gondii bradyzoites in human myotubes and their metabolomic characterization.

Authors:  Céline Christiansen; Deborah Maus; Ellen Hoppenz; Mateo Murillo-León; Tobias Hoffmann; Jana Scholz; Florian Melerowicz; Tobias Steinfeldt; Frank Seeber; Martin Blume
Journal:  Nat Commun       Date:  2022-03-04       Impact factor: 14.919

6.  Coordinated loading of IRG resistance GTPases on to the Toxoplasma gondii parasitophorous vacuole.

Authors:  Aliaksandr Khaminets; Julia P Hunn; Stephanie Könen-Waisman; Yang O Zhao; Daniela Preukschat; Jörn Coers; Jon P Boyle; Yi-Ching Ong; John C Boothroyd; Gabriela Reichmann; Jonathan C Howard
Journal:  Cell Microbiol       Date:  2010-01-26       Impact factor: 3.715

7.  Significant performance variation among PCR systems in diagnosing congenital toxoplasmosis in São Paulo, Brazil: analysis of 467 amniotic fluid samples.

Authors:  Thelma Suely Okay; Lidia Yamamoto; Léa Campos Oliveira; Erika Regina Manuli; Heitor Franco de Andrade Junior; Gilda Maria Barbaro Del Negro
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

8.  Immunopathogenesis of toxoplasmosis in pregnancy.

Authors:  J Dupouy-Camet
Journal:  Infect Dis Obstet Gynecol       Date:  1997

9.  Assessment of laboratory methods used in the diagnosis of congenital toxoplasmosis after maternal treatment with spiramycin in pregnancy.

Authors:  Isolina Mx Rodrigues; Tatiane L Costa; Juliana B Avelar; Waldemar N Amaral; Ana M Castro; Mariza M Avelino
Journal:  BMC Infect Dis       Date:  2014-06-24       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.